SOURCE: Duravest, Inc.

July 11, 2006 07:30 ET

Duravest Subsidiary, PST GmbH, Appoints First Members of New Medical and Scientific Advisory Board

CHICAGO, IL and MUNICH, GERMANY -- (MARKET WIRE) -- July 11, 2006 -- Duravest, Inc. (PINKSHEETS: DUVT) (XETRA: DUV), the global leader in investing in and developing convergent medical technology firms, is pleased to report that PST GmbH, its German subsidiary specializing in its patented non-invasive osteoarthritis and sports injury treatments, has launched its combined new Medical and Scientific advisory board with two high profile appointments.

The appointments are that of Professor Dr. Michael Faensen, a highly experienced hip and knee replacement specialist from the Turzak Medical Group in Berlin, and University Professor Dr. Reinhard Weinstabl, a renowned sports traumatologist from the Wiener Privatklinik in Vienna. These globally recognized and leading clinicians are both highly experienced in orthopedics with a keen sense for innovative, non-invasive treatment modalities for osteoarthritis and sports-related injuries.

As members of PST's Medical and Scientific Advisory Board, Drs. Faensen and Weinstabl will closely support the PST team in developing and evaluating ongoing clinical trial protocols, assist with spearheading potential studies involving their own institutions, and providing consultation for innovative new product development and expansion. Dr. Ogan Gurel, CEO of Duravest, Inc. and acting CEO of PST, GmbH, commented, "The addition of these two prominent members of the European orthopedic community will be invaluable in assuring the highest level of rigor and innovation for both the ongoing and future product development initiatives at our PST GmbH subsidiary."

Superior Safety Profile for PST

To date, there are no reported side effects from PST treatments. Over the past 10 years in which PST has been commercially available, with approximately 400,000 patients treated worldwide, there have been no reported side effects of any significant nature. This is to be compared to the significant risks that accompany other conservative treatments such as non-steroidal anti-inflammatory drugs, Cox-2 inhibitors or narcotics. To this end, Dr. Harald Martin, Medical Director at PST GmbH, said, "These pain-killers provide mostly symptomatic relief while the PST treatment also accelerates the fundamental healing process."

Efficacy Studies Highly Successful

Besides pain reduction and increase in strength and mobility of the treated joint, documented in many clinical trials, a substantial regeneration of cartilage tissue has also been seen as a result of PST treatment. A recently completed in vitro study at the Laboratory for Tissue Engineering at the Charité Hospital in Berlin has demonstrated that PST had an effect on the expression of chondrocyte marker genes in osteoarthritis-affected chondrocytes and reverted the expression of selected marker genes towards the pattern found in normal chondrocytes. These studies substantiate in basic science terms some of the mechanism of action at a cytobiological level for the PST treatment.

About Prof. Dr. Faensen

Prof. Dr. Faensen was previously Director of the Clinic for Trauma and Reconstructive Surgery at Auguste-Viktoria Hospital from 1989 to 2003. In 2003 he established and has since directed the Center for Hip Joint Surface Replacement at the DRK Clinics in Berlin. Prof. Dr. Faensen noted, "I am delighted to play a role on the PST Medical and Scientific Advisory Board. In my experience, osteoarthritis patients, whose joint degeneration is not severe enough to require a replacement, can benefit enormously by the PST treatment." While a recognized expert in the surgical management of degenerative joint disease, Prof. Dr. Faensen appreciates the opportunities to treat osteoarthritis patients non-surgically using the Pulsed Signal Therapy (PST) technique.

About Prof. Dr. Weinstabl

Prof. Dr. Weinstabl is a renowned academician and clinician who specializes in non-invasive treatments for trauma and sports injuries. He is a faculty member at the Department of Traumatic Surgery of the University Hospital of Vienna and is widely published in the scientific literature including the New England Journal of Medicine. Prof. Dr. Weinstabl is convinced that Pulsed Signal Therapy widens the therapeutic spectrum for sports-related injuries, especially if the soft tissues such as ligaments or tendons are involved. Prof. Dr. Weinstabl commented, "PST's patented system plays an important role in my treatment options with patients. It still continues to astonish me how quickly the PST treatment can enable professional athletes can return to normal training, even after a severe injury."

About Duravest, Inc.

Duravest, Inc. (PINKSHEETS: DUVT) (XETRA: DUV) is a publicly traded holding company that initiates and develops strategic investments in next-generation convergent medical technologies. Duravest currently has two subsidiaries: Estracure, Inc., based in Montreal, Canada, which is developing a next-generation coronary stent based on proprietary 17-beta-estradiol; and PST GmbH, based in Munich, Germany, which currently markets patented bio-magnetic therapies for a number of orthopedic conditions and their associated pain management.

Safe Harbor Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals or assumptions of future events are not statements of historical fact and may be considered forward-looking statements. They involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated.

Contact Information